RetinaLogik
Portable VR-based vision screening platform for accessible and efficient eye care.
Website: https://www.retinalogik.com/
Cover Block
Open sources
| Attribute | Details |
|---|---|
| Name | RetinaLogik |
| Tagline | Portable VR-based vision screening platform for accessible and efficient eye care. |
| Headquarters | Calgary, Canada |
| Founded | 2021 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Hardware |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Seed (total disclosed ~$1,100,000) |
Links
Open sources
- Website: https://www.retinalogik.com/
- LinkedIn: https://www.linkedin.com/company/retinalogik
What an Investor Needs First
Open sources RetinaLogik is a Calgary-based startup building a portable, VR-based vision screening platform that aims to address the persistent challenge of accessible, low-cost eye care, a proposition that has recently gained tangible validation through a $1.1 million funding round and Health Canada Class II medical device approval [BetaKit, February 2025]. The company was spun out from the University of Calgary in 2021, founded by Dr. Abdullah Sarhan and Julia St. Amand after Sarhan's research trip to Uganda highlighted the need for more deployable diagnostic tools [University of Calgary, August 2023]. Its core product, the RVF200 headset, is a software layer that runs on commercial VR hardware, allowing patients to self-administer visual field tests with guidance in over 35 languages while specialists review results remotely via a web portal [retinalogik.com, retrieved 2024]. This approach differentiates by decoupling the testing hardware from expensive, stationary clinical equipment, targeting workflow improvements of up to 35% for clinics and expanding reach into rural communities, senior homes, and telehealth models [Angel Investors Ontario, February 2024].
The founding team combines deep technical research with operational focus. CEO Abdullah Sarhan holds a PhD and led the underlying research, while COO Julia St. Amand, a recent graduate with dual degrees in Commerce and Kinesiology, manages the company's business development and strategy [BetaKit, February 2025]. The recent seed financing, supported by a syndicate of regional angels and venture funds including York Angel Investors and UCeed, provides capital to execute on commercial deployments following regulatory clearance [Business Wire, March 2025]. Over the next 12-18 months, the key milestones to watch are the scaling of its reported North American clinic deployments into measurable revenue, the pursuit of additional regulatory approvals for broader market access, and the translation of its partnership discussions with NGOs and health authorities into contracted pilots [Trico Foundation, November 2021].
Verified against public records -- Core claims on funding, regulatory status, product, and team are confirmed by multiple independent sources including BetaKit, Business Wire, and the University of Calgary.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Hardware |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Seed (total disclosed ~$1,100,000) |
Inside the Company
Open sources
RetinaLogik began as a research project at the University of Calgary, where co-founder Dr. Abdullah Sarhan was completing his PhD in biomedical engineering. The company was formally spun out and founded in 2021 after Sarhan and co-founder Julia St. Amand decided to pursue the venture full-time [University of Calgary, August 2023]. The impetus for the technology reportedly came from Sarhan's research trip to Uganda, which highlighted the acute need for accessible, portable vision screening tools in underserved communities [University of Calgary, August 2023]. The company is headquartered in Calgary, Canada [BetaKit, February 2025].
Key early milestones include acceptance into the Life Sciences Fellowship (LSF) accelerator program in March 2022 [University of Calgary, August 2023]. The company's primary regulatory milestone was achieved in early 2025, with the announcement of Health Canada Class II medical device approval for its technology [BetaKit, February 2025] [Business Wire, March 2025]. This approval coincided with the closure of a $1.1 million seed funding round in March 2025 [BetaKit, February 2025].
Verified against public records -- Confirmed by University of Calgary, BetaKit, and Business Wire.
Under the Hood
Reported and inferred
The core product is a portable visual field testing system built on commercially available virtual reality hardware, a design choice that separates its clinical software from the cost and complexity of custom-built medical devices. RetinaLogik's RVF200 headset, described as "portable" and "patient-friendly" on its website, is the physical interface for a suite of vision screening tests [retinalogik.com, retrieved 2024]. The software can be loaded onto standard VR headsets, allowing patients to self-administer tests with guidance available in over 35 languages, a feature aimed at reducing language barriers in diverse clinical settings [retinalogik.com, retrieved 2024] [University of Calgary, retrieved 2024]. Results are transmitted to a secure web portal for remote review by eye care specialists, creating a telehealth-enabled workflow [Perplexity Sonar Pro Brief, retrieved 2024].
From a clinical and regulatory standpoint, the platform's recent Health Canada Class II medical device approval represents a significant milestone, validating the technology for diagnostic use in the Canadian market [BetaKit, February 2025]. The company claims its integrated approach can improve clinic workflow efficiency by up to 35%, though this figure is sourced from marketing materials [retinalogik.com, retrieved 2024]. Public traction signals are limited but include a claim that the device is "now being used in clinics across North America," though specific clinic names or deployment counts are not provided [Angel Investors Ontario, February 2024].
Partially corroborated -- Product features and regulatory status are confirmed by company and press sources; specific technical architecture and performance claims are sourced from the company.
Market Research
Open sources
Access to vision care is a persistent global challenge, but the market for solutions that can decentralize testing is being reshaped by converging trends in telehealth, aging demographics, and the maturation of consumer hardware platforms. The core opportunity for RetinaLogik exists at the intersection of these forces, targeting the replacement of stationary, expensive clinical equipment with a portable, software-defined alternative.
Quantifying the total addressable market for portable visual field testing is not straightforward from public sources. The company's own stated goal is to reach 2 million people by 2026 [Trico Foundation, November 2021], a figure that serves as a directional target rather than a validated market size. For context, the broader global ophthalmic devices market was valued at approximately $32.5 billion in 2022 and is projected to grow at a compound annual rate of 5.2% through 2030, according to a Grand View Research report [Grand View Research, 2023]. While this analogous market includes a wide range of surgical, diagnostic, and vision correction devices, it underscores the scale of spending in eye care infrastructure where RetinaLogik's diagnostic tools would compete.
Several demand drivers are clear from the cited research. The primary tailwind is the structural shortage of eye care specialists, particularly in rural and remote communities, which creates a need for tools that enable technicians or patients to conduct preliminary screenings under remote supervision [University of Calgary, August 2023]. A second driver is the aging global population, which increases the prevalence of conditions like glaucoma that require regular visual field monitoring. Finally, the widespread adoption of telehealth during the pandemic has normalized remote consultation models, making healthcare providers more receptive to platforms that separate the testing location from the specialist's review.
Key adjacent and substitute markets include traditional perimetry equipment sold by established medtech players, which represents the incumbent solution RetinaLogik aims to displace. Another adjacent market is the broader field of remote patient monitoring (RPM) platforms, where RetinaLogik's technology could be integrated as a specialized module. Regulatory forces are a critical gating factor, as evidenced by the company's recent Health Canada Class II medical device approval [BetaKit, February 2025]. This classification indicates the device is considered to pose a moderate to high risk, requiring a demonstrated safety and efficacy profile for market entry, and sets a precedent for future regulatory submissions in other jurisdictions.
| Metric | Value |
|---|---|
| Global Ophthalmic Devices Market (2022) | 32.5 $B |
| Projected CAGR (2022-2030) | 5.2 % |
| Company's 2026 User Target | 2 million people |
The available sizing data highlights the ambition of the company's user target against the backdrop of a large but slow-growing incumbent market. The 2 million person goal implies a rapid deployment scale that would require significant commercial execution beyond the current clinic deployments.
Partially corroborated -- Market size figures are from an analogous third-party report; company-specific target is from a single early-stage interview.
Competition and Substitutes
Reported and inferred
RetinaLogik enters a market defined by large, stationary incumbent equipment and a nascent field of digital challengers, positioning its portable VR headset as a bridge between clinical-grade accuracy and community-based accessibility.
No named competitors were identified in the captured sources, which complicates a direct feature-to-feature comparison. The competitive map is therefore best understood in segments. The primary incumbents are the manufacturers of traditional perimeters and visual field analyzers, such as those from Zeiss and Heidelberg Engineering. These devices are the gold standard in ophthalmology and optometry clinics but are expensive, bulky, and require dedicated space and trained technicians to operate. RetinaLogik's wedge is not to displace these devices in high-volume specialty centers, but to expand testing capacity into settings they cannot economically serve: rural clinics, community health centers, nursing homes, and telehealth programs [Perplexity Sonar Pro Brief, retrieved 2024].
Adjacent substitutes include a growing category of smartphone-based vision screening apps and tablet-based perimeter tests. These offer extreme portability and low cost but generally lack the standardized, controlled testing environment and regulatory approvals required for definitive clinical diagnosis. RetinaLogik's defensible edge rests on its regulatory clearance as a Class II medical device [BetaKit, February 2025], which validates its clinical accuracy and is a significant barrier to entry for software-only applications. This edge is durable in the near term, as regulatory pathways are time-consuming and capital-intensive, but it is perishable if a well-funded digital health competitor secures similar approval for a software-only or alternative hardware solution.
The company is most exposed on the commercial front. Its current distribution appears reliant on partnerships with NGOs and health authorities for community care models [Trico Foundation, November 2021], a channel that may not scale as quickly or profitably as direct sales to established eye care clinics. Furthermore, while the use of commercial VR headsets lowers hardware costs, it also creates a dependency on third-party hardware ecosystems (like Meta's Quest) and could expose the company to competition from the hardware makers themselves should they decide to develop or acquire similar diagnostic software.
The most plausible 18-month competitive scenario hinges on execution in two key areas: commercial traction and technological iteration. If RetinaLogik can successfully convert its early North American clinic deployments [Angel Investors Ontario, February 2024] into a repeatable sales motion with enterprise health systems, it becomes the de facto leader in portable, regulated visual field testing. The winner in this scenario is the company that first proves a scalable B2B sales model beyond pilot projects. Conversely, if adoption remains limited to small-scale community pilots, the loser is the company that fails to demonstrate economic viability to institutional investors ahead of a necessary Series A. The risk is that a larger medical device company with an existing sales force into eye clinics could develop or acquire a comparable VR-based solution, leveraging its distribution to overtake a capital-constrained pioneer.
Partially corroborated -- Competitive analysis is inferred from product positioning and market structure; no direct competitor names were confirmed in public sources.
Opportunity
Open sources The prize for RetinaLogik is a reconfiguration of the global vision screening market, shifting a traditionally hardware-bound, clinic-centric process to a software-defined, distributed service.
The headline opportunity is to become the standard platform for decentralized visual field testing, particularly in underserved and remote care settings. This outcome is reachable, not merely aspirational, because the company has already secured the foundational regulatory clearance required to sell its product as a medical device in a major market. Health Canada Class II approval, announced in March 2025, validates the core technology for clinical use and removes a primary barrier to commercial adoption [BetaKit, February 2025]. The wedge is a portable, patient-administered test that runs on commercial VR hardware, a model that directly addresses documented access barriers in rural communities and for patients with mobility challenges [University of Calgary, August 2023]. By turning a fixed, expensive piece of clinic equipment into a portable software application, RetinaLogik positions itself to capture demand from healthcare providers seeking to extend their reach and improve operational efficiency, a need the company claims its platform can address by improving workflow efficiency by up to 35% [retinalogik.com, retrieved 2024].
The path to scaling this platform involves several concrete scenarios, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Telehealth Standard | RetinaLogik becomes the preferred vision screening tool for large telehealth providers and remote patient monitoring programs. | A partnership with a major national telehealth platform or insurer to integrate RetinaLogik's tests into their standard assessment protocol. | The company's model is built for remote specialist review and is already described as being used in a telehealth community-care model through NGO and health authority partnerships [Trico Foundation, November 2021] [Angel Investors Ontario, February 2024]. |
| Public Health Deployment | Provincial or state health authorities adopt the platform for widespread community screening programs, targeting conditions like glaucoma. | A successful pilot study with a public health unit demonstrating cost savings and increased screening rates in a target population. | The technology's multilingual capability (guidance in over 35 languages) and portability are tailored for diverse public health initiatives [retinalogik.com, retrieved 2024] [University of Calgary, retrieved 2024]. |
| Clinic Footprint Expansion | The RVF200 headset becomes a common piece of equipment in optometry and ophthalmology clinics across North America, displacing older perimeters. | Securing a distribution partnership with a major medical equipment supplier or optical wholesaler. | The product is already reported to be in use in clinics across North America, indicating early commercial traction and clinician acceptance [Angel Investors Ontario, February 2024]. |
What compounding looks like for RetinaLogik is a classic data and workflow flywheel. Each new clinic deployment generates more patient test data, which can be used to refine the underlying algorithms and improve test accuracy and speed. More accurate and efficient tests increase clinician trust and adoption, leading to more deployments. This creates a data moat: a proprietary dataset of visual field results linked to patient demographics and test conditions that would be difficult for a new entrant to replicate. Furthermore, workflow integration compounds value. Once a clinic integrates the RetinaLogik software and portal into its daily operations, switching costs increase. The platform's ability to streamline scheduling, testing, and remote review creates a sticky ecosystem where adding new test types or analytical features for the same installed base becomes the logical next step.
The size of the win can be framed by looking at the market for traditional visual field analyzers. While a direct public comparable is scarce, the global market for ophthalmic diagnostic equipment was valued at over $3 billion in recent years, with perimeters being a significant segment. If RetinaLogik successfully executes on the "Clinic Footprint Expansion" scenario and captures even a single-digit percentage of the North American installed base for visual field testing, it could support a business with tens of millions in annual recurring revenue. In a successful outcome, the company's value would be driven by its software margins and recurring service model, not hardware sales alone. A plausible exit scenario could involve acquisition by a larger medical device company seeking to modernize its diagnostic portfolio or a telehealth platform looking to vertically integrate a key diagnostic capability. This represents a scenario where the company transitions from a niche hardware+software provider to a platform business, a transformation that would command a significant premium over its current seed-stage valuation (scenario, not a forecast).
Partially corroborated -- The core regulatory approval and product claims are well-sourced from the company and press. The growth scenarios are extrapolated from cited partnership models and early deployment claims, which lack specific customer names or contract values.
Sources
Open sources
[BetaKit, February 2025] RetinaLogik ready to execute on vision with $1.1-million financing, Health Canada Class II approval | https://betakit.com/retinalogik-ready-to-execute-on-vision-with-1-1-million-financing-health-canada-class-ii-approval/
[University of Calgary, August 2023] Researcher works to eliminate barriers to eye exams using artificial intelligence and virtual reality | https://ucalgary.ca/news/researcher-works-eliminate-barriers-eye-exams-using-artificial-intelligence-and-virtual-reality
[retinalogik.com, retrieved 2024] RetinaLogik - The new paradigm in vision testing | https://www.retinalogik.com/
[Angel Investors Ontario, February 2024] RetinaLogik - Within Sight, Within Reach | https://www.angelinvestorsontario.ca/companies/retinalogik
[Trico Foundation, November 2021] 10 Questions with RetinaLogik: A “Getting to Know Our Calgary…” | https://tricofoundation.ca/10-questions-with-retinalogik-a-getting-to-know-our-calgary/
[Business Wire, March 2025] RetinaLogik Secures $1.1 Million in Funding and Health Canada Class II Medical Device Approval | https://www.businesswire.com/news/home/20250317109280/en/RetinaLogik-Secures-1.1-Million-in-Funding-and-Health-Canada-Class-II-Medical-Device-Approval
[Startup Canada, December 2022] Empathetic Leadership with Julia St.Amand | https://www.startupcan.ca/blog/empathetic-leadership-with-julia-stamand/
[Grand View Research, 2023] Ophthalmic Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/ophthalmic-devices-market
Articles about RetinaLogik
- RetinaLogik's VR Headset Clears Health Canada for the Remote Eye Exam — The Calgary startup's portable vision testing platform, now approved as a Class II medical device, aims to bring specialist-grade screening to rural clinics and senior homes.